? Biostatistics Shared Resource The Biostatistics Shared Resource (BSR) is a SJCCC managed shared resource with the overarching mission of impacting pediatric cancer through biostatistics collaboration and consulting, and through comprehensive, effective, and timely biostatistical support to Center members. BSR has a highly experienced and interactive team of biostatisticians who work collaboratively with researchers who are conducting leading edge basic science, clinical research, and population and survivorship research from the 5 SJCCC Programs. This is evidenced by the high level of collaborative publications and key scientific contributions in high-impact journals such as Journal of Clinical Oncology (n=31), Cancer (n=31), Nature Genetics (n=9), and Lancet Oncology (n=4). In addition, BSR biostatisticians are well integrated into the clinical trial teams providing statistical support throughout the life cycle of the research project from concept development through publication. During the last funding period, 85% of all SJCCC publications used the BSR and 77% (n=358/468) of all collaborative publications with a biostatistician as a co-author were associated with SJCCC programs. These included papers from all 5 of the programs: CCSP (n = 103), CBP (n = 1), DBSTP (n = 66), NBTP (n = 83), and HMP (n = 105). A total of 125 St. Jude investigators and their staff used the BSR during the index year (FY2017). Of those, 71 (57%) were SJCCC members. The BSR faculty also offer workshops, office consultations, lectures, seminars, Grand Rounds, and courses on study design, analysis methods, and software implementation to fellows, research staff, and faculty. The BSR is led by Dr. Deo Kumar Srivastava who has more than 23 years' experience in the statistical design and analysis of cancer research and cancer clinical trials. He is supported by 9 faculty biostatisticians and 13 master's-level trained staff, ensuring that BSR support is available to investigators throughout all 5 programs. During our most recent funding period, BSR has witnessed growth driven by the strengthening of the scientific programs, research in genomic characterization of pediatric cancers, and focus on complex precision medicine SJCCC investigator-initiated multisite trials. Goals for the next funding period include continuing to provide state-of-the-art statistical support to all SJCCC investigators including new investigators, and targeted recruitment of biostatisticians to strengthen expertise in personalized medicine, immunotherapy, and in expansion of high-throughput big data. Lastly, BSR will closely partner with the Information Services department in the implementation of the new software provided by the Clinical Trials Management System.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA021765-41
Application #
9883738
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-03-01
Budget End
2021-02-28
Support Year
41
Fiscal Year
2020
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Dove, Austin P; Manole, Bogdan-Alexandru; Wakefield, Daniel V et al. (2018) Managing local-regional failure in children with high-risk neuroblastoma: A single institution experience. Pediatr Blood Cancer 65:e27408
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Chamdine, Omar; Elhawary, Ghada Ahmad Saad; Alfaar, Ahmad Samir et al. (2018) The incidence of brainstem primitive neuroectodermal tumors of childhood based on SEER data. Childs Nerv Syst 34:431-439
Heitzer, Andrew M; Ashford, Jason M; Harel, Brian T et al. (2018) Computerized assessment of cognitive impairment among children undergoing radiation therapy for medulloblastoma. J Neurooncol :
Robinson, Katherine M; Yang, Wenjian; Haidar, Cyrine E et al. (2018) Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies. Pharmacogenomics J :
Teitz, Tal; Fang, Jie; Goktug, Asli N et al. (2018) CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 215:1187-1203
Binder, Randall J; Hatfield, M Jason; Chi, Liying et al. (2018) Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors. Eur J Med Chem 149:79-89
Slayton, William B; Schultz, Kirk R; Kairalla, John A et al. (2018) Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. J Clin Oncol 36:2306-2314
Donohoe, Clare; Bosi, Judy K; Sykes, April et al. (2018) Clinical Characteristics of Children and Adolescents Undergoing Hematopoietic Cell Transplantation Who Develop Oral Mucositis. Oncol Nurs Forum 45:457-462
Green, Daniel M; Wang, Mingjuan; Krasin, Matthew J et al. (2018) Serum ALT elevations in survivors of childhood cancer. A report from the St. Jude Lifetime Cohort Study. Hepatology :

Showing the most recent 10 out of 6764 publications